Safety & Effectiveness of the BEAM Device in Mild-to-moderate Acne
Primary Purpose
Acne
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
BEAM device
Sponsored by
About this trial
This is an interventional treatment trial for Acne focused on measuring Acne
Eligibility Criteria
Inclusion Criteria:
- Age 15 years or older of either gender and of any racial/ethnic group.
- At least 8 acne inflammatory lesions (see section 9) in the treatment and control areas.
- Presence of clinically-evident facial acne of mild-to-moderate severity (score 2-4 on the Global Acne Severity Scale, see below)
- Subjects must be in generally good health.
- Subjects must be able and willing to comply with the requirements of the protocol.
Exclusion Criteria:
- Oral retinoid use within six months of entry into the study.
- Systemic acne therapies (oral antibiotics) within 2 weeks of entry into the study.
- Topical acne therapies (retinoids, antibiotics) within 1 week of entry into the study.
- Microdermabrasion or superficial chemical peels at the site to be treated within 2 months of entry into the study.
- Subjects with a history of dermabrasion or laser resurfacing at the site to be treated.
- Use of topical lipid absorbing substances (Clinac AC) within 1 week of entry into the study.
- Non-compliant subjects.
- Subjects with a significant medical history or concurrent illness/condition which the investigator(s) feel is not safe for study participation.
- Subjects using alcohol-based topical solutions or "exfoliating" agents within 1 week of entry into the study.
- Subjects with a history of very frequent herpes simplex infections of the face or with clinical evidence of active herpes simplex infections.
- Pregnant or nursing females.
- Subjects with known photosensitivity disorders felt by the investigators to preclude safe inclusion in the study.
- Subjects who have a history of significant post-inflammatory hyperpigmentation at the sites of acne lesions.
Sites / Locations
- Baumann Cosmetic & Research Institute
- Grekin Skin Institute
- Oregon Dermatology & Research Institute
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
All subjects
Arm Description
All subjects are enrolled in this arm and will use the BEAM device on one side of the face and the other side of the face will be the control
Outcomes
Primary Outcome Measures
Reduction in inflammatory lesion count
Reduction in the number of inflammatory acne lesions on one side of the face after 8 weeks of treatment.
Secondary Outcome Measures
Global Acne Severity Score
Reduction in the Global Acne Severity Score at 8-weeks of treatment
Full Information
NCT ID
NCT01162837
First Posted
July 13, 2010
Last Updated
May 1, 2012
Sponsor
Oregon Aesthetic Technologies
1. Study Identification
Unique Protocol Identification Number
NCT01162837
Brief Title
Safety & Effectiveness of the BEAM Device in Mild-to-moderate Acne
Official Title
An Evaluation of the Safety and Effectiveness of the BEAM Device in the Treatment of Mild-to-moderate Acne
Study Type
Interventional
2. Study Status
Record Verification Date
May 2012
Overall Recruitment Status
Completed
Study Start Date
June 2010 (undefined)
Primary Completion Date
September 2010 (Actual)
Study Completion Date
October 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Oregon Aesthetic Technologies
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study will determine if the use of the BEAM device reduces the signs and symptoms of mild-to-moderate acne.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acne
Keywords
Acne
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
Outcomes Assessor
Allocation
Non-Randomized
Enrollment
33 (Actual)
8. Arms, Groups, and Interventions
Arm Title
All subjects
Arm Type
Other
Arm Description
All subjects are enrolled in this arm and will use the BEAM device on one side of the face and the other side of the face will be the control
Intervention Type
Device
Intervention Name(s)
BEAM device
Intervention Description
A red/blue LED device for the treatment of acne
Primary Outcome Measure Information:
Title
Reduction in inflammatory lesion count
Description
Reduction in the number of inflammatory acne lesions on one side of the face after 8 weeks of treatment.
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
Global Acne Severity Score
Description
Reduction in the Global Acne Severity Score at 8-weeks of treatment
Time Frame
8-weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
15 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age 15 years or older of either gender and of any racial/ethnic group.
At least 8 acne inflammatory lesions (see section 9) in the treatment and control areas.
Presence of clinically-evident facial acne of mild-to-moderate severity (score 2-4 on the Global Acne Severity Scale, see below)
Subjects must be in generally good health.
Subjects must be able and willing to comply with the requirements of the protocol.
Exclusion Criteria:
Oral retinoid use within six months of entry into the study.
Systemic acne therapies (oral antibiotics) within 2 weeks of entry into the study.
Topical acne therapies (retinoids, antibiotics) within 1 week of entry into the study.
Microdermabrasion or superficial chemical peels at the site to be treated within 2 months of entry into the study.
Subjects with a history of dermabrasion or laser resurfacing at the site to be treated.
Use of topical lipid absorbing substances (Clinac AC) within 1 week of entry into the study.
Non-compliant subjects.
Subjects with a significant medical history or concurrent illness/condition which the investigator(s) feel is not safe for study participation.
Subjects using alcohol-based topical solutions or "exfoliating" agents within 1 week of entry into the study.
Subjects with a history of very frequent herpes simplex infections of the face or with clinical evidence of active herpes simplex infections.
Pregnant or nursing females.
Subjects with known photosensitivity disorders felt by the investigators to preclude safe inclusion in the study.
Subjects who have a history of significant post-inflammatory hyperpigmentation at the sites of acne lesions.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ben Ehst, MD
Organizational Affiliation
Oregon Health and Science University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Baumann Cosmetic & Research Institute
City
Miami Beach
State/Province
Florida
ZIP/Postal Code
33140
Country
United States
Facility Name
Grekin Skin Institute
City
Warren
State/Province
Michigan
ZIP/Postal Code
48088
Country
United States
Facility Name
Oregon Dermatology & Research Institute
City
Portland
State/Province
Oregon
ZIP/Postal Code
97210
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Safety & Effectiveness of the BEAM Device in Mild-to-moderate Acne
We'll reach out to this number within 24 hrs